en
/
sv
About Elicera
Elicera in briefBoardTeamAdvisors
Immuno-oncology
What is immuno-oncology?
Oncolytic virusCAR T-cell therapy
Technology
CAR T-cell therapyChallengesMode-of-actionScientific publications
Pipeline
PipelineELC-100ELC-201ELC-301ELC-401Clinical trialsPatent portfolio
Investors
Press ReleasesCorporate GovernanceThe ShareFinancial ReportsFinancial CalendarEventsIPOAnalyst Coverage
News
NewsPress Releases
Events
Contact

Investors

Welcome to Elicera's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders.

If you need more information or have any questions, please contact Jamal El-Mosleh, CEO.
‍
Phone: +46(0)703 31 90 51
Email: info@elicera.com

Press Releases

March 6, 2023
Regulatory
Erik Penser Bank initiates coverage on Elicera Therapeutics
Read more
March 1, 2023
Regulatory
Elicera Therapeutics hires Erik Penser Bank as market maker
Read more
February 17, 2023
Regulatory
Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022
Read more
All Press Releases

Corporate Governance

The following sections contain information that are relevant for Elicera's corporate governance.

Articles of AssociationGeneral MeetingBoardManagementAuditorCertified Adviser

The Share

Elicera Therapeutics is listed on Nasdaq First North Growth Market. The company has issued one class of shares and the total number of shares amounts to 19 782 000.

Read about the Share

Financial Reports

Front cover of an Elicera report
Latest report:
February 17, 2023
Q4 report 2022
All Financial Reports

Financial Calendar

See the calendar

Analyst Coverage

Read the latest analysis on Elicera here:

Penser Future (in Swedish)
All analyses
Follow us
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.